Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is an **oral fixed-dose combination** of risedronate sodium (a bisphosphonate), calcium (typically as the carbonate or citrate salt), and vitamin D3 (cholecalciferol). It is intended for the treatment and prevention of osteoporosis and related conditions, particularly in postmenopausal women or at-risk adults. - **Risedronate sodium**: Inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone, thereby reducing bone turnover and increasing bone mineral density. - **Calcium**: Essential mineral for bone formation and maintenance; supplementation helps supply adequate substrate for bone mineralization. - **Vitamin D3**: Active form (cholecalciferol); promotes intestinal absorption of calcium and phosphate, maintains serum calcium and phosphate levels, and enables normal bone mineralization. This combination addresses key factors in osteoporosis: limiting bone loss (risedronate), ensuring adequate calcium for bone, and enabling effective calcium absorption and metabolism (vitamin D3). Primary indication: osteoporosis (treatment and prevention) and related bone disorders in populations at risk of calcium or vitamin D deficiency.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on risedronate sodium + calcium + vitamin D3.